Tumor Immunotherapy Composition Using Microbial Innate Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and passive immunotherapy, fail to systematically address tumor metastasis and restore immune surveillance mechanisms, with T-cell-based immunotherapies showing limited efficacy and significant toxic side effects.
Innovation Solution
A pharmaceutical composition comprising microbial agents like Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi, combined with polyinosinic acid, polycytidylic acid, and vitamin, stimulates the innate immune system to activate adaptive immunity, enhancing tumor-specific responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell-based immunotherapy is used, then adaptive immune response is stimulated, but response rate remains low and toxic side effects occur
Solution Approach 1:
The patent segments the immune system into innate and adaptive components, using innate immune stimulants (cyclic ADP-ribse, bacterial products) as a separate first line of action that activates adaptive immunity indirectly, thereby avoiding the direct toxicities of T cell-based therapies while maintaining effective tumor response
Solution Approach 2:
The patent introduces innate immune stimulants as intermediary substances that bridge the gap between tumor treatment and adaptive immune activation. These intermediaries (cyclic ADP-ribse, bacterial cell wall products) activate macrophages and dendritic cells, which then stimulate T cell responses without requiring direct T cell targeting, thus avoiding the toxicities associated with T cell-based immunotherapies
2Reliability
If chemotherapy is used, then cancer cells are killed effectively, but normal cells are damaged and immune system is impaired
Solution Approach 1:
The patent converts the harmful non-selective killing mechanism of chemotherapy into a beneficial selective immune activation mechanism. Instead of directly killing cancer cells (which damages normal cells), the therapy uses innate immune stimulants to activate the body's own immune surveillance mechanisms, turning the harm of non-selective toxicity into the benefit of selective immune-mediated cancer elimination
Solution Approach 2:
The patent enables the immune system to perform self-service by using innate immune stimulants that activate endogenous immune cells (macrophages, dendritic cells, T cells) to recognize and eliminate cancer cells. This self-service mechanism eliminates the need for external cytotoxic agents that damage normal cells, as the body's own immune system performs the cancer-killing function selectively
3Reliability
If surgery and radiotherapy are used, then localized lesions are eliminated, but disseminated disease cannot be eradicated
Solution Approach 1:
The patent creates a universal therapy that can address both localized and disseminated cancer through the activation of systemic immune surveillance. The innate immune stimulants trigger a systemic immune response that can detect and eliminate cancer cells anywhere in the body, making the therapy universally applicable to various cancer stages and locations, unlike surgery and radiotherapy that are limited to localized treatment
4Reliability
If targeted therapy is used, then specificity is improved, but scope of action is limited and drug resistance remains
Solution Approach 1:
The patent introduces dynamic adaptability through innate immune stimulants that can activate different immune cell types and signaling pathways based on the tumor's characteristics. This dynamic immune activation allows the therapy to adapt to various tumor types and stages, overcoming the fixed specificity of targeted therapies and addressing drug resistance by continuously evolving the immune response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively activates the immune system to target cancer cells with minimal side effects, reducing treatment costs and improving treatment outcomes for various cancers, including solid tumors, while being broadly applicable and safe.
Implementation Method 1
stimulates the innate immune system to activate adaptive immunity, enhancing tumor-specific responses
Data Source
AI summary
The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.